Rubedo Life Sciences
Rubedo Life Sciences is a clinical stage biotech company dedicated to discovering and developing medicines to keep individuals biologically young by targeting the cells that drive aging and diseases. Founded by leading scientists and entrepreneurs, the company aims to extend human health span through innovative research in aging, regenerative medicine, and drug discovery, leveraging artificial intelligence and informatics.
Industries
Nr. of Employees
small (1-50)
Rubedo Life Sciences
Products
Clinical-stage senescence-targeted small-molecule candidate (topical formulation)
A clinical-stage small-molecule modulator targeting senescent-cell biology, progressed to first-in-human topical dosing in Phase I to assess safety and preliminary clinical effects in dermatologic and inflammatory indications.
Multi-omics discovery and senescent-cell phenotyping platform
An internal platform combining multi-omics assays and computational analysis to identify and phenotype senescent cell populations across tissues, supporting target selection and screening workflows; platform outputs supported by peer-reviewed publications.
Preclinical senolytic prodrug candidate (proof-of-concept)
A preclinical senolytic prodrug asset that demonstrated reversal of frailty and cognitive deficits in aged mouse models, serving as translational proof-of-concept for targeting senescent cells.
Preclinical pulmonary fibrosis program targeting senescent lung cells
A preclinical program focused on targeting senescent lung and progenitor cells for treatment of pulmonary fibrosis, developed in collaboration with academic medical centers and supported by translational research awards.
Clinical-stage senescence-targeted small-molecule candidate (topical formulation)
A clinical-stage small-molecule modulator targeting senescent-cell biology, progressed to first-in-human topical dosing in Phase I to assess safety and preliminary clinical effects in dermatologic and inflammatory indications.
Multi-omics discovery and senescent-cell phenotyping platform
An internal platform combining multi-omics assays and computational analysis to identify and phenotype senescent cell populations across tissues, supporting target selection and screening workflows; platform outputs supported by peer-reviewed publications.
Preclinical senolytic prodrug candidate (proof-of-concept)
A preclinical senolytic prodrug asset that demonstrated reversal of frailty and cognitive deficits in aged mouse models, serving as translational proof-of-concept for targeting senescent cells.
Preclinical pulmonary fibrosis program targeting senescent lung cells
A preclinical program focused on targeting senescent lung and progenitor cells for treatment of pulmonary fibrosis, developed in collaboration with academic medical centers and supported by translational research awards.
Services
Integrated drug discovery and translational development
End-to-end programs from target discovery and validation through translational modeling, formulation, IND-enabling activities and early clinical development.
Clinical development and investigator engagement
Protocol design, trial initiation and execution support for first-in-human and early-phase studies, including safety monitoring, regulatory filing assistance and access to dermatology/oncodermatology investigator networks.
Computational and data infrastructure services
Development and operation of distributed data infrastructures, large-scale analysis pipelines, and chemistry-focused machine learning tools to accelerate discovery.
Industry collaboration and licensing for consumer products
Strategic co-development and licensing arrangements with consumer and personal-care partners to translate therapeutic discovery into skincare and cosmeceutical products.
Translational internships and training
On-site, mentored internship projects providing hands-on training in translational research and regenerative-medicine techniques.
Integrated drug discovery and translational development
End-to-end programs from target discovery and validation through translational modeling, formulation, IND-enabling activities and early clinical development.
Clinical development and investigator engagement
Protocol design, trial initiation and execution support for first-in-human and early-phase studies, including safety monitoring, regulatory filing assistance and access to dermatology/oncodermatology investigator networks.
Computational and data infrastructure services
Development and operation of distributed data infrastructures, large-scale analysis pipelines, and chemistry-focused machine learning tools to accelerate discovery.
Industry collaboration and licensing for consumer products
Strategic co-development and licensing arrangements with consumer and personal-care partners to translate therapeutic discovery into skincare and cosmeceutical products.
Translational internships and training
On-site, mentored internship projects providing hands-on training in translational research and regenerative-medicine techniques.
Expertise Areas
- Senescence-targeted small-molecule therapeutics
- Medicinal chemistry and prodrug design
- Multi-omics target discovery and bioinformatics
- In vivo translational pharmacology and humanized disease models
Key Technologies
- Prodrug design and optimization
- Small-molecule medicinal chemistry and solid-phase combinatorial chemistry
- GPX4 pathway modulation
- Next-generation sequencing and transcriptomics